FDA grants first MRTP authorizations for ZYN nicotine pouches

The U.S. Food and Drug Administration (FDA) has issued Modified Risk Tobacco Product (MRTP) authorizations for 20 ZYN nicotine pouch varieties. This marks the first time such authorizations have been granted to nicotine pouches in the United States.

These authorizations allow Philip Morris International (PMI) to communicate that using ZYN instead of cigarettes reduces the risk of certain smoking-related illnesses, including mouth cancer, cardiovascular disease, lung cancer, stroke, emphysema, and chronic bronchitis. PMI U.S. leadership stated the decision provides adult nicotine consumers with access to science-based information regarding risk reduction.

In conjunction with these regulatory developments, PMI is expanding the ZYN portfolio in the U.S. market. The company is introducing new nicotine strengths of 1.5mg and 8mg to complement its existing 3mg and 6mg options. This expansion aims to cater to diverse consumer preferences across various flavors and formats, including the higher-moisture ZYN ULTRA line.